Latest News and Press Releases
Want to stay updated on the latest news?
-
600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens. Results from this landmark study...
-
Phase 2 clinical trial will be presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) conference in Brussels, Belgium on March 19, 2025. COO Valerie Ceva will...
-
Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is an immune system regulator that interrupts the...
-
Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is an immune system regulator that interrupts the...
-
NORTH BRUNSWICK, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that its...
-
BioAegis announces global Phase 2 study of its inflammation regulator protein, gelsolin, for the treatment of Acute Respiratory Distress Syndrome (ARDS).
-
Partnership supports execution of a large phase 2 global study to evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK, N.J., Oct....
-
NORTH BRUNSWICK, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing novel therapies for inflammatory diseases through a portfolio built around...
-
Gelsolin decreased microparticle-driven inflammation and mitigated activation of the NLRP3 inflammasome in type 2 diabetes. Low levels of gelsolin identified in individuals with type 2 diabetes...
-
NORTH BRUNSWICK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma...